These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15102927)

  • 1. Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
    Vanover KE; Harvey SC; Son T; Bradley SR; Kold H; Makhay M; Veinbergs I; Spalding TA; Weiner DM; Andersson CM; Tolf BR; Brann MR; Hacksell U; Davis RE
    J Pharmacol Exp Ther; 2004 Sep; 310(3):943-51. PubMed ID: 15102927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
    Vanover KE; Weiner DM; Makhay M; Veinbergs I; Gardell LR; Lameh J; Del Tredici AL; Piu F; Schiffer HH; Ott TR; Burstein ES; Uldam AK; Thygesen MB; Schlienger N; Andersson CM; Son TY; Harvey SC; Powell SB; Geyer MA; Tolf BR; Brann MR; Davis RE
    J Pharmacol Exp Ther; 2006 May; 317(2):910-8. PubMed ID: 16469866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
    Gleason SD; Shannon HE
    Psychopharmacology (Berl); 1997 Jan; 129(1):79-84. PubMed ID: 9122367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
    Abekawa T; Honda M; Ito K; Koyama T
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):247-56. PubMed ID: 12898123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
    J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
    Ninan I; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
    Funakoshi T; Chaki S; Kawashima N; Suzuki Y; Yoshikawa R; Kumagai T; Nakazato A; Kameo K; Goto M; Okuyama S
    Life Sci; 2002 Aug; 71(12):1371-84. PubMed ID: 12127158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.
    Reavill C; Kettle A; Holland V; Riley G; Blackburn TP
    Br J Pharmacol; 1999 Feb; 126(3):572-4. PubMed ID: 10188965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
    Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
    J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward.
    Benaliouad F; Kapur S; Rompré PP
    Neuropsychopharmacology; 2007 Mar; 32(3):551-61. PubMed ID: 16794561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
    Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
    Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.